Literature DB >> 8630378

Long-term leukemia-initiating capacity of a CD34-subpopulation of acute myeloid leukemia.

W Terpstra1, A Prins, R E Ploemacher, B W Wognum, G Wagemaker, B Löwenberg, J J Wielenga.   

Abstract

Acute myeloid leukemia (AML) proliferation in vivo is maintained by a small fraction of progenitor cells. These cells have been assumed to express an immature phenotype and to produce most colony-forming units (CFU-AML). For one case of AML (French-American-British [FAB] M1, normal cytogenetics), we examined the capacity of the CD34+ (25% of unseparated AML cells) and CD34- fractions to initiate leukemia in severe combined immunodeficient (SCID) mice. In addition, the production of CFU-AML and nucleated cells (NC) of these subsets was investigated in long-term bone marrow culture (LTBMC). The frequencies of cobblestone area-forming cells (CAFC) were also estimated; early appearing cobblestone areas (CAs) are indicative of relatively mature progenitors and late CAs represent the progeny of primitive progenitors. In mice transplanted with CD34- (98% pure) or CD34+ (98% pure) grafts, similar AML cell growth was seen throughout an observation period of 106 days. The capacity to establish long-term growth from the CD34- cells was confirmed by renewed outgrowth after retransplantation. In vitro, the CD34- fraction contained both immature and mature CAFCs and produced high numbers of CFU-AML and NC in LTBMC. The CD34+ fraction produced only small numbers of CFU-AML, NC, and mature CAFCs. Therefore, the expression of CD34 and the content of CFU-AML were not associated with long-term growth of AML. However, similar frequencies of primitive CAFCs were observed in both fractions. Thus, both CD34- and CD34+ subsets of this AML sample contained immature progenitors with the capacity to initiate long-term AML growth as characterized in vivo (in SCID mice) as well as in vitro (in CAFC assay), indicating asynchrony between functional and immunophenotypical maturation of AML progenitor cell compartments.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8630378

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

Review 1.  Integration of hypoxic HIF-α signaling in blood cancers.

Authors:  L Schito; S Rey; M Konopleva
Journal:  Oncogene       Date:  2017-05-22       Impact factor: 9.867

Review 2.  Leukemic stem cells: identification and clinical application.

Authors:  Diana Hanekamp; Jacqueline Cloos; Gerrit Jan Schuurhuis
Journal:  Int J Hematol       Date:  2017-03-29       Impact factor: 2.490

3.  Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction.

Authors:  David C Taussig; Jacques Vargaftig; Farideh Miraki-Moud; Emmanuel Griessinger; Kirsty Sharrock; Tina Luke; Debra Lillington; Heather Oakervee; Jamie Cavenagh; Samir G Agrawal; T Andrew Lister; John G Gribben; Dominique Bonnet
Journal:  Blood       Date:  2010-01-06       Impact factor: 22.113

4.  Niche-based screening identifies small-molecule inhibitors of leukemia stem cells.

Authors:  Kimberly A Hartwell; Peter G Miller; Siddhartha Mukherjee; Alissa R Kahn; Alison L Stewart; David J Logan; Joseph M Negri; Mildred Duvet; Marcus Järås; Rishi Puram; Vlado Dancik; Fatima Al-Shahrour; Thomas Kindler; Zuzana Tothova; Shrikanta Chattopadhyay; Thomas Hasaka; Rajiv Narayan; Mingji Dai; Christina Huang; Sebastian Shterental; Lisa P Chu; J Erika Haydu; Jae Hung Shieh; David P Steensma; Benito Munoz; Joshua A Bittker; Alykhan F Shamji; Paul A Clemons; Nicola J Tolliday; Anne E Carpenter; D Gary Gilliland; Andrew M Stern; Malcolm A S Moore; David T Scadden; Stuart L Schreiber; Benjamin L Ebert; Todd R Golub
Journal:  Nat Chem Biol       Date:  2013-10-27       Impact factor: 15.040

5.  CD200 expression marks leukemia stem cells in human AML.

Authors:  Jenny M Ho; Stephanie M Dobson; Veronique Voisin; Jessica McLeod; James A Kennedy; Amanda Mitchell; Liqing Jin; Kolja Eppert; Gary Bader; Mark D Minden; John E Dick; Jean C Y Wang
Journal:  Blood Adv       Date:  2020-11-10

Review 6.  The role of cancer stem cells in the modulation of anti-tumor immune responses.

Authors:  Cristina Maccalli; Kakil Ibrahim Rasul; Mamoun Elawad; Soldano Ferrone
Journal:  Semin Cancer Biol       Date:  2018-09-24       Impact factor: 15.707

Review 7.  The Role of Autophagy and lncRNAs in the Maintenance of Cancer Stem Cells.

Authors:  Leila Jahangiri; Tala Ishola; Perla Pucci; Ricky M Trigg; Joao Pereira; John A Williams; Megan L Cavanagh; Georgios V Gkoutos; Loukia Tsaprouni; Suzanne D Turner
Journal:  Cancers (Basel)       Date:  2021-03-11       Impact factor: 6.639

8.  CD138- multiple myeloma cells express high level of CHK1 which correlated to overall survival in MM patient.

Authors:  Dong Wu; Peihua Zhang; Fangmei Li; Ying Shen; Hongli Chen; Yuandong Feng; Aili He; Fangxia Wang
Journal:  Aging (Albany NY)       Date:  2020-11-10       Impact factor: 5.682

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.